STOCK TITAN

MacroGenics (MGNX) director Koenig has 52,829 RSUs vest under separation deal

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MACROGENICS INC director Scott Koenig reported the vesting and conversion of restricted stock units (RSUs) into common shares. On 2025-08-13, a total of 52,829 RSUs (21,165 and 31,664 units) were exercised or converted into 52,829 shares of common stock at a stated price of $0.00 per share.

According to a Separation and Consulting Agreement between the company and Koenig, 50% of each outstanding and unvested RSU immediately vested, and the vested shares are to be delivered to him as soon as practicable after the vesting date. Each RSU represents a contingent right to receive one common share.

Positive

  • None.

Negative

  • None.
Insider Koenig Scott
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit 21,165 $0.00 $0.00
Exercise Restricted Stock Unit 31,664 $0.00 $0.00
Exercise Common Stock 21,165 $0.00 $0.00
Exercise Common Stock 31,664 $0.00 $0.00
Holdings After Transaction: Restricted Stock Unit — 52,828 shares (Direct); Common Stock — 830,244 shares (Direct)
Footnotes (2)
  1. F1. Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting.
  2. F2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
RSUs exercised/converted 52,829 shares Total RSUs (21,165 and 31,664) converted to common stock on 2025-08-13
Common shares received 52,829 shares Shares of MacroGenics common stock corresponding to vested RSUs
Transaction date 2025-08-13 Date of RSU vesting and conversion events
Exercise/transaction price $0.00 per share Stated price for RSU conversion into common stock
RSU block 1 21,165 units First RSU tranche vested and converted into common stock
RSU block 2 31,664 units Second RSU tranche vested and converted into common stock
Immediate vesting percentage 50% Portion of each outstanding and unvested RSU that immediately vested under Separation Agreement
Restricted Stock Unit financial
"Each restricted stock unit (RSU) represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Separation and Consulting Agreement financial
"Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person"
contingent right financial
"Each restricted stock unit (RSU) represents a contingent right to receive one share"

FAQ

What did MacroGenics (MGNX) insider Scott Koenig report in this Form 4?

Scott Koenig reported the vesting and conversion of 52,829 restricted stock units into an equal number of MacroGenics common shares on 2025-08-13, tied to his Separation and Consulting Agreement with the company.

How many MacroGenics (MGNX) RSUs vested for Scott Koenig on 2025-08-13?

On 2025-08-13, 52,829 restricted stock units vested and were converted for Scott Koenig, in two blocks of 21,165 and 31,664 RSUs, each RSU corresponding to one MacroGenics common share.

What agreement governed Scott Koenig’s RSU vesting at MacroGenics (MGNX)?

The RSU vesting was governed by a Separation and Consulting Agreement between MacroGenics and Scott Koenig, under which 50% of each outstanding and unvested RSU immediately vested as of the specified date.

Did MacroGenics (MGNX) report a cash exercise price for Koenig’s RSU conversion?

The filing lists a transaction and exercise price of $0.00 per share for the RSU conversions, reflecting that restricted stock unit settlements typically do not involve a cash exercise price paid by the reporting person.

How many MacroGenics (MGNX) common shares did Scott Koenig receive from RSUs?

Scott Koenig became entitled to 52,829 MacroGenics common shares upon vesting, matching the 52,829 restricted stock units, with delivery to occur as soon as practicable after the vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Koenig Scott

(Last) (First) (Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 M 21,165(1) A $0(2) 798,580 D
Common Stock 08/13/2025 M 31,664(1) A $0(2) 830,244 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0(2) 08/13/2025 M 21,165 (1) (1) Common Stock 21,165 $0 21,165 D
Restricted Stock Unit $0(2) 08/13/2025 M 31,664 (1) (1) Common Stock 31,664 $0 31,663 D
Explanation of Responses:
1. Pursuant to the Separation and Consulting Agreement between the Company and the Reporting Person (the "Separation Agreement"), 50% of the shares with respect to each outstanding and unvested restricted stock unit (RSU) immediately vested. Vested shares will be delivered to the Reporting Person as soon as practicable after the date of vesting.
2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
Remarks:
/s/ Beth A. Smith, Attorney-in-fact 08/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.